NetworkNewsBreaks – Merus N.V. (NASDAQ: MRUS) Secures $79.2 Million in Underwritten Public Offering
Merus N.V. (NASDAQ: MRUS), a clinical-stage bispecific antibody company developing Biclonics(R), has closed an underwritten public offering of 5,462,500 of its common shares, which includes 712,500 additional shares per the full exercise of the over-allotment option granted to the underwriters. Merus N.V. secured approximately $79.2 million in gross proceeds from the offering, with each of the shares sold at the public offering price of $14.50. The company intends to use the proceeds to advance clinical development of its product candidates, preclinical research and technology development, as well as for working capital and other general corporate purposes. ROTH Capital Partners acted…







